Cryoport vs Ligand Pharmaceuticals
CYRX and LGND side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CYRX and LGND compare
Ligand Pharmaceuticals is the larger company, worth 6.1 times as much as Cryoport ($6.2B against $1.0B).
Cryoport grew revenue faster over the last twelve months (11.8% versus 1.0% for Ligand Pharmaceuticals).
Ligand Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of 20.3% compared with −21.5% at Cryoport.
Cryoport scores higher on the StockData Score (10 against 6 for Ligand Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CYRX | LGND |
|---|---|---|
| Size and price | ||
| Market cap | $1.0B | $6.2B |
| Share price | $19.89 | $308.79 |
| Change, 1 year | 125% | 50.2% |
| Change, 5 years | −72.5% | 90.7% |
| Beta (5Y) | 1.92 | 1.30 |
| Employees | 738 | 47 |
| StockData Score | ||
| Total score | 10 (better) | 6 |
| Valuation score | 1 (better) | 0 |
| Growth score | 2 (better) | 1 |
| Performance score | 3 | 3 |
| Health score | 4 (better) | 2 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 135× |
| P/S | 5.2× (better) | 24.3× |
| P/B | 2.1× (better) | 6.4× |
| EV/EBITDA | – | 113× |
| P/FCF | – | 68.2× |
| FCF yield | −1.9% | 1.5% (better) |
| Fair value | $15.89 | $55.48 |
| Margin of safety | −25.2% (better) | −457% |
| Growth | ||
| Revenue growth (TTM) | 11.8% (better) | 1.0% |
| Revenue growth, 5Y average | 17.5% (better) | 10.4% |
| Net income growth (TTM) | −158% | 5.9% (better) |
| EPS growth (TTM) | −178% | 18.7% (better) |
| Profitability | ||
| Gross margin | 46.9% | – |
| Operating margin | −20.0% | 10.1% (better) |
| Net margin | −21.5% | 20.3% (better) |
| FCF margin | −9.8% | 35.7% (better) |
| Return on equity | −8.3% | 5.4% (better) |
| Return on invested capital | −32.9% | 2.6% (better) |
| Financial health | ||
| Debt / equity | 0.00 (better) | 1.17 |
| Net debt / EBITDA | – | 11.26 |
| Interest coverage | −18.3× | 3.1× (better) |
| Current ratio | 2.04 (better) | 1.22 |
| Altman Z-score | 1.38 | 3.46 (better) |
| Piotroski F-score | 5 | 6 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 93.9% | 113% |
| Held by insiders | 3.6% | 2.6% |
| Insider net buying, 12 months | −$6.3M (better) | −$35.7M |
| Short interest, % of float | 7.1% | – |
Go deeper
- CYRX stock overview
- CYRX income statement
- CYRX valuation and score
- LGND stock overview
- LGND income statement
- LGND valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.